Amitis Ramezani; Ali Eslamifar; Arezoo Aghakhani; Ebrahim Kalantar; Mohammad Banifazl; Akbar Velayati
Volume 4, Issue 2 , April 2009, , Pages 71-74
Abstract
Background and Objective: The outcome of hepatitis B virus (HBV) infection may be influenced by host factors like Human Leukocyte Antigen (HLA). We have investigated HLA-A and DRB1 alleles in patients with persistent hepatitis B infection compared to subjects who had spontaneously recovered from ...
Read More
Background and Objective: The outcome of hepatitis B virus (HBV) infection may be influenced by host factors like Human Leukocyte Antigen (HLA). We have investigated HLA-A and DRB1 alleles in patients with persistent hepatitis B infection compared to subjects who had spontaneously recovered from HBV infection. To complete the findings of this study we performed another survey in certain HLA alleles that were significantly related to the outcome of HBV infection. The current study aimed to determine association between HBV infection outcome and HLA-A and DRB1 genotyping in North part of Iran. Patients and Methods: Ninety-four HBV infected patients were enrolled in this cross sectional study. First HLA-A and DRB1 alleles were analyzed by using low resolution PCR sequence-specific-primer (PCR-SSP) and then we used high resolution PCR-SSP method for subtyping HLA-A*33 and DRB1*13 alleles which were significantly related to the outcome of HBV infection. Results: HLA-A*33 allele was significantly higher in persistent group than recovered group and sub typing showed HLA-A*3303 in 75% and HLA-A*3301 in 25% of cases. HLA-DRB1*13 allele was significantly lower in persistent group than in recovered group and its subtypes were DRB1*1301 in 66.7% and DRB1*1303 in 33.3% of subjects. Conclusion: Host HLA polymorphism is an important factor to determining the outcome of HBV infection. HLA-A*3303 and DRB1*1301 were the predominant subtypes of HLA-A*33 and DRB1*13 alleles in Iranian HBV infected patients.
Arezoo Aghakhani; Amitis Ramezani; Minoo Mohraz; Mohammad Banifazl; Ali Eslamifar
Volume 4, Issue 2 , April 2009, , Pages 80-84
Abstract
Background and Objective: Presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is defined, as isolated anti-HBc. little is known about the clinical significance of the isolated anti-HBc in hepatitis ...
Read More
Background and Objective: Presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is defined, as isolated anti-HBc. little is known about the clinical significance of the isolated anti-HBc in hepatitis B virus (HBV) infections. The aim of this study was to assess the significance of anti-HBc as the only marker of HBV infection in high risk patients. Patients and Methods: In this cross-sectional study, 395 patients including 289 patients on chronic hemodialysis (HD) and 106 HIV infected subjects were enrolled. HBsAg, anti-HBs, anti-HBc, Hepatitis C antibody (anti-HCV) and Alanine aminotransferase (ALT) levels were tested in all subjects. The presence of HBV-DNA was determined quantitatively in plasma samples of patients with isolated anti-HBc by real-time PCR. Results: Of 395 patients, 40 (10.13%, 95% CI, 7.1%-13.1%) had isolated anti-HBc. HBV-DNA was detectable in 12 of 40 patients (30%, 95% CI, 15.8%-44.2%) who had isolated anti-HBc. Conclusion: Our study showed that detection of isolated anti-HBc could reflect unrecognized HBV infection; hence, screening of these patients is useful to preventing of HBV transmission.
Amitis Ramezani; Arezoo Aghakhani; Mohammad Reza Sharif; Mohammad Banifazl; Ali Eslamifar; Ali Akbar Velayati
Volume 3, Issue 3 , June 2008, , Pages 125-128
Abstract
Background and Objective: Anemia is a common manifestation of human immunodeficiency virus (HIV) infection, occurring in approximately 30% of patients with asymptomatic infection and in as many as 75% to 80% of those with AIDS. Anemia has been associated with decreased quality of life and decreased ...
Read More
Background and Objective: Anemia is a common manifestation of human immunodeficiency virus (HIV) infection, occurring in approximately 30% of patients with asymptomatic infection and in as many as 75% to 80% of those with AIDS. Anemia has been associated with decreased quality of life and decreased survival. In this study we aimed to determine the prevalence and related factors of anemia in HIV-infected patients. Materials and Methods: A total of 143 HIV positive patients who referred to behavioral disease consulting center in Tehran were screened for anemia. Mild to moderate anemia was defined as hemoglobin (Hb) 8-14g/dl for men and 8-12g/dl for women; severe anemia was defined as Hb less than 8g/dl for both males and females. sociodemographic data were collected using a questionnaire. In all patients, CD4 lymphocytes counting were done by flowcytometry. Results: It was found out that 143 HIV positive patients with a mean age of 37.1+ 2 years were enrolled in our study. The mean Hb level was 13.5 ± 2.1 g/dl. Mild anemia occurred in 46% of subjects while severe anemia was not observed. There was not any significant difference between patients with and without anemia regarding age, gender, stage of the infection, CD4 cells count and concurrent anti-retroviral therapy. We also found significant difference between anemia and risk behaviors for HIV acquisition. Conclusion: Our results showed that mild to moderate anemia was frequent in HIV positive patients but severe anemia was not prevalent in this study population.
Sara Jam; Duman Sabzevari; Arezoo Aghakhani; Ali Eslamifar; Mohammad Banifazl; Amitis Ramezani
Volume 2, Issue 4 , September 2007, , Pages 144-148
Abstract
Background and Objective: Pseudomonas aeruginosa has become a frequent cause of nosocomial infections, particularly in intensive care units (ICUs). Many reports have documented high rates of resistance in this species to commonly-used broad-spectrum antibiotics. The aim of this study was to assess the ...
Read More
Background and Objective: Pseudomonas aeruginosa has become a frequent cause of nosocomial infections, particularly in intensive care units (ICUs). Many reports have documented high rates of resistance in this species to commonly-used broad-spectrum antibiotics. The aim of this study was to assess the in vitro activity of some antibiotics against Pseudomonas aeruginosa strains to determine the susceptibility patterns of isolates to different antibiotics. Materials and Methods: A total of 233 Pseudomonas aeruginosa isolates obtained from various clinical specimens of hospitalized children in Ali-Asghar hospital of Tehran (Iran) were considered for susceptibility test. These strains were tested against 12 different antibiotics by a disk diffusion method. Of these isolates, 33.9% were from trachea, 31.8% from urine, 6.9% from eye, 5.2% from blood, 5.1% from ear, 1.3% from cerebrospinal fluid, 1.2% from stool, and 14.6% from other sites. In addition, 48.5% of P. aeruginosa strains were isolated from patients in ICUs. Results: The most active antimicrobials were amikacin and other active compounds were gentamicin, ceftazidime, and ciprofloxacin respectively. Isolates from ICUs were more resistant to amikacin and gentamicin as compared to those from non-ICU wards (p<0.05). Isolates from trachea were more resistant to amikacin, gentamicin, ciprofloxacin and ceftazidime than those from other sites (p<0.05). Conclusion: Our study showed that amikacin was the most active agent against P. aeruginosa followed by gentamycin, ceftazidime, and ciprofloxacin. According to our in vitro study results, active antibiotic susceptibility testing and surveillance should be continued in order to curtail the problem of antibiotic resistance.
Amitis Ramezani; Minoo Mohraz; Mohammad Banifazl; Latif Gachkar; Sara Jam; Ali Eslamifar; Farhad Yaghmaie; Kambiz Nemati; Arezoo Aghakhani
Volume 2, Issue 4 , September 2007, , Pages 154-158
Abstract
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients ...
Read More
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients receiving highly active antiretroviral therapy (HAART) and antiretroviral-naive patients. Patients and Methods: Forty HIV infected patients treated by HAART as a case group (6 females and 34 males) with a mean age of 40.7 ± 10 years and 15 HIV naïve as a control group (2 females and 13 males) with a mean age of 38.40 ± 8.3 enrolled in this study. The two groups were well matched in respect to age, sex and CD4 cell counts. A standardized questionnaire with epidemiological, clinical, and therapeutic data was completed by physicians. Blood samples were obtained for metabolic measurements. CD4 positive cell count was measured by f lowcytometry. Results: Levels of total cholesterol, triglycerides, LDL, HDL, lactate, and FBS were elevated in 24%, 37%, 3.7%, 44.4%, 29.6% and 11% of patients respectively. There was a significant difference regarding mean total cholesterol and LDL between treated group and controls (p<0.05). There was also no significant difference between treated group and controls regarding triglyceride, HDL, lactate and FBS levels. Conclusion: Our study demonstrated that metabolic abnormalities are relatively common in HIV-infected patients receiving HAART. Therefore, it is recommended to screen the HIV infected patients on HAART for metabolic disorders, potential of morbidity, and possible long-term cardiovascular risk factors.
